



# Enduring an incurable illness

**Dr. Aryan Gupta**

**Fellow in Pediatric Neurology**

**Dr. D.Y Patil Medical College, Hospital and Research Center, Pune**

**Under the guidance of –**

**Dr. Shailaja Mane – Professor and HOD Pediatrics**

**Dr. Shiji Chalipat - Professor, Pediatric neurologist**

3-year-old male child presented with complaints of –

- ✓ **Fever** since 7 days
- ✓ On Day 5 – **Altered sensorium** in the form of drowsiness and **Increased work of breathing**
- ✓ On Day 6 – **Multiple episodes of Vomiting** and **Multiple episodes of generalized tonic-clonic seizures**

- ✓ No history suggestive of cranial nerve palsy
- ✓ No history of tuberculosis contact
- ✓ No history of weakness of limbs
- ✓ No history of recent infection or vaccination
- ✓ No history of visual impairment
- ✓ No history of animal contact or bite
- ✓ No history of recent travel

## Outside hospital course



- ✓ Patient was admitted in a hospital outside where he was stabilized and shifted to pediatric intensive care unit of the same hospital
- ✓ He was started on Ceftriaxone, Oseltamivir, Acyclovir and Levetiracetam
- ✓ Chest Xray was done findings of which were consistent with **bronchopneumonia**





### Investigations

- ✓ Hb – 12.5
- ✓ TLC – 16,500 (N/L – 46/40)
- ✓ Platelets – 246,000
- ✓ CRP – 54
- ✓ LFT – WNL
- ✓ RFT – WNL
- ✓ Serum electrolytes - WNL

### Lumbar puncture –

- ✓ Cells – **22 (80% - Lymphocytes, 20% - Neutrophils)**
- ✓ Proteins – 32.9
- ✓ Glucose – 62
- ✓ RBCs - 0
- ✓ MRI Brain with Contrast





## Outside hospital course

- ✓ CSF Biofires was done which was **negative**
- ✓ Nasopharyngeal swab Biofires was also done which was suggestive of parainfluenza virus infection



- ✓ In view of clinical presentation and neuroimaging findings possibility of **demyelination/Auto-immune encephalitis** was considered
- ✓ Patient was started on Methylprednisolone and IVIG (single dose at 1g/kg)
- ✓ During further course of stay **progressive deterioration in sensorium**, new onset **squint of left eye**, **papilledema** and **hypertensive readings** were noted



- ✓ **Anti cerebral oedema** measures were started

✓ After 7 days of outside hospital stay (14<sup>th</sup> day of the onset of illness) patient got admitted at Dr. D.Y Patil Medical College and hospital, Pune

On admission –

- ✓ GCS – 7/15 (E2V2M3)
- ✓ Temperature – Febrile (101°F)
- ✓ HR – 112/min
- ✓ PP – Normal volume
- ✓ RR – 56/min with intercostal and subcostal retractions
- ✓ BP – 116/96 mm Hg (>99<sup>th</sup> centile)
- ✓ Spo2 – 98% on O2 by nasal prongs

✓ Normal anthropometric measures

✓ No dysmorphism

✓ No neurocutaneous markers



## **CNS examination**

- ✓ HMF – **Drowsy**
- ✓ GCS – 7/15 (E2V2M3)
- ✓ Cranial nerve examination -
- ✓ Pupils - bilaterally equal and reactive
- ✓ Fundus – Changes of **papilledema**
- ✓ **Left lateral rectus palsy** s/o 6<sup>th</sup> nerve affection
- ✓ Rest of the cranial nerve examination - normal


- ✓ Motor examination –
- ✓ Tone – **Spasticity** present in both upper and lower limb (**Grade - 1**)
- ✓ Power – >3/5
- ✓ **Brisk DTRs**
- ✓ **Extensor plantar**
  
- ✓ Sensory system – withdrawal to pain present
- ✓ Cerebellar signs – Not present
- ✓ Meningeal signs – **Neck rigidity** and **Kernig's sign present**

- ✓ *Respiratory system* – **Bilateral crepitations**
- ✓ *Per Abdomen* - No organomegaly



✓ Eye movements – suggestive of **Oculogyric crisis**


✓ Bedside EEG – **No ictal correlate** - Diffuse delta slowing – Suggestive of Encephalopathy



✓ **Autonomic fluctuation** – Blood pressure, Heart rate and temperature were noticed

*Picture taken and displayed with due consent from the parents*

✓ Chest Xray – Fluffy interstitial infiltrates s/o atypical pneumonia



## Summary

- ✓ 3-year-old male child with normal birth, development and family history presented with complaints of -
- ✓ Fever, cough, cold, respiratory distress
- ✓ Altered sensorium and
- ✓ Multiple episodes of seizures
- ✓ On examination the patient had a GCS of 7/15, signs of respiratory distress, autonomic fluctuations with positive pyramidal and extrapyramidal findings, signs of raised ICT and positive meningeal signs.

On the basis of history and examination following differential diagnoses were considered -

- ✓ **Tubercular meningitis**
- ✓ **Viral encephalitis (Possibility of Parainfluenza, Adenoviral, Enteroviral, Epstein bar virus)**
- ✓ **Mycoplasma encephalitis**
- ✓ **Autoimmune encephalitis**
- ✓ **Acute Demyelination Syndrome**

## Investigations



- ✓ Complete blood count, C-Reactive Protein, Liver and Renal function test, Serum electrolytes

## Investigations




- ✓ *Hb* – 12.5
- ✓ *TLC* – 14,500 (*N/L* – 60/40)
- ✓ *Platelets* – 212,000
- ✓ *CRP* – 24
- ✓ *LFT* – *WNL*
- ✓ *RFT* – *WNL*
- ✓ *Serum electrolytes* - *WNL*



## **Investigations**

- ✓ Repeat MRI Brain with contrast and whole spine screening









## *Investigations*

✓ Repeat Lumbar puncture

### *Lumbar puncture –*

- ✓ Cells – 30 (100% Lymphocytes)
- ✓ Proteins – 57.6 (Previous - 29)
- ✓ Glucose – 75 (BSL - 92)
- ✓ RBCs - 0

## *Investigations*

- ✓ TB work up and CSF CBNAAT - Negative
- ✓ Serum Mycoplasma IgM antibody – Positive
- ✓ CSF Auto-immune encephalitis panel – Negative
  - ✓ Serum EBV IgM antibody – Negative
- ✓ Japanese encephalitis CSF IgM and PCR – Negative
  - ✓ Serum MOG and AqPo4 antibody - Negative

## Treatment

✓ Ceftriaxone (100 mg/kg/day), Acyclovir(60 mg/kg/day), Levetiracetam (40 mg/kg/day), Fosphenytoin (5 mg/kg/day), Oseltamivir (3 mg/kg/day), 3% NaCl (1 ml/kg/hour) were continued

✓ At this stage, we considered 2 possibilities –

✓ **1. Mycoplasma encephalitis** and

✓ **2. Sero-negative Auto-immune encephalitis**

✓ **Azithromycin** (10 mg/kg/day) was started in view of Mycoplasma encephalitis

✓ **IVIg** (1 g/kg/day) and **Methylprednisolone** (30 mg/kg/day) was continued in view of possibility of Auto-immune encephalitis

- ✓ On day 4 of admission (Day 18 of illness) – No improvement in sensorium was observed
- ✓ **Levofloxacin** was also started which has been proven efficacious in cases of **Azithromycin resistant Mycoplasma encephalitis**



- ✓ Day 8 of admission (Day 22 of illness) – IVIG, Methylprednisolone, Azithromycin, Levofloxacin - **no improvement in the sensorium** was seen
- ✓ **Progressive increase in dystonia and opisthotonic posturing** was observed

✓ Parents revealed a crucial history, which was concealed initially

✓ A history of scratch below the right nostril resulting in a lacerated wound of 1 x 0.5 cm by a rabid dog which was later found to be deceased – WHO Category 3 rabies virus exposure 2 weeks before the onset of illness was revealed

✓ By the time child was admitted, scratch was completely healed

✓ Child received Anti-rabies vaccine on day 0, 3 and 7

✓ Equine rabies Immunoglobulin on day 0 (dose of 40 IU/kg)

✓ However, when the patient was scheduled for the 4<sup>th</sup> dose of the vaccine, he began developing symptoms for which he was then admitted

- ✓ In view of a category 3 rabies exposure, possibility of **Rabies Encephalitis** was now considered
- ✓ We discussed the case with the National Institute of Virology, Pune as our patient did not exhibit **classical signs such as hydrophobia or aerophobia or neuroparalysis** and was administered both vaccine and immunoglobulin



✓ We were then advised to send the following samples considering the rare possibility of the **non-classical form** of Rabies encephalitis–

- 3 serial saliva samples 4 hours apart
- CSF
- Serum
- Skin biopsy from the nape of the neck

| Result of Molecular Testing for Rabies |                     |   |                              |
|--|---------------------|---|------------------------------|
| Sample ID                              | Sample Type         | Test performed  | Result                       |
| 2411764                                | Saliva              | Real-time Reverse Transcription Polymerase Chain Reaction | No rabies virus RNA detected |
| 2411765                                | Cerebrospinal fluid |   |                              |
| 2411767                                | Neck skin biopsy    |   |                              |

| Result of Serological Testing for Rabies |                     |   |  |
|--|---------------------|---|--|
| Sample ID                                | Sample Type         | Test performed                          | Result   |
| 2411765                                  | Cerebrospinal fluid | Rapid Fluorescent Focus Inhibition Test | Rabies virus neutralizing antibodies detected (Titre: 128)               |
| 2411766                                  | Serum               |   | Rabies virus neutralizing antibodies detected (Titre: Greater than 1024) |

# Diagnostic criteria for Rabies Encephalitis

✓ Any detectable antibodies in a single CSF sample (irrespective of prior vaccination status)





or


✓ Detectable antibodies in serum sample of patients with no prior vaccination

or

✓ In patients who have received prior rabies vaccination (partial or complete) - Paired serum sample demonstrating a 4-fold or greater rise in antibody titres

✓ A **repeat MRI Brain** was done at **36 days** after the onset of illness in view of the progressive clinical deterioration





1. Considering the history of **category 3 rabies exposure** (2 weeks before the onset of illness)

**2. Progressive clinical course**

**3. Progressive atrophy of cerebrum, cerebellum, caudate and thalamus**

**4. Presence of neutralizing rabies antibodies in the CSF**

✓ A diagnosis of **atypical/Non-classical form of Rabies encephalitis** was confirmed

- ✓ The patient was shifted to ward after 21 days of stay in PICU
  - ✓ Physiotherapy
  - ✓ Anti-dystonic/Anti-spasticity medicines
  - ✓ Ankle foot orthosis
  - ✓ Anti-seizure medication (Levetiracetam)
  - ✓ Frequent position change and water bed
  - ✓ High calorie and protein diet via nasogastric tube
  - ✓ Anti-mycoplasma treatment was given for 14 days
  - ✓ Multi-vitamins and calcium supplements
  - ✓ The patient was started on **Amantadine** based on the evidence from case reports
- For dystonia, spasticity and contractures
- Prevention of bed sores

- ✓ 62 days since the onset of illness
- ✓ Currently in persistent vegetative state
- ✓ mRS (Modified Rankin Score) of 5
- ✓ Respiratory infection has settled
- ✓ Intermittent autonomic fluctuation in blood pressure, heart rate and temperature
- ✓ Severe dystonia
- ✓ Ankle contractures



*Picture taken and displayed with due consent from the parents*

# Rabies Infection

- ✓ Rabies is one of the **oldest known diseases** in history with cases dating back to 4000 years ago
- ✓ The origin of the word rabies is from the latin word “**rabere**” which translates to “**to rage**”
- ✓ Rabies virus causes an **acute progressive encephalomyelitis** in humans and kills up to 70000 people/year worldwide and 20,000 people in India
- ✓ Usually transmitted through the **saliva of an infected animal**, rabies encephalitis has the **highest fatality rate (virtually 100%)** among infectious diseases
- ✓ Dogs, the main rabies reservoir species, usually infect by an unprovoked bite.
- ✓ **Survival from rabies is rarely seen, with fewer than 20 adequately documented cases reported worldwide**



✓ There are **5 stages** of rabies following inoculation:

**Stage – 1 - Incubation;**

**Stage – 2 - Prodrome;**

**Stage – 3 - Acute neurologic illness;**

## Stage – 3 - *Acute neurologic illness;*

3 types

**1. Encephalitic (Furious) form** – Most common (85%)

- ✓ Hydrophobia
- ✓ Aerophobia
- ✓ Altered sensorium,
- ✓ Autonomic dysfunction (tachycardia, tachypnoea, fever fluctuation in blood pressure)

**2. Paralytic form** – Less common (<20%)

- ✓ Maybe confused with **GBS**
- ✓ May have altered sensorium, fever and bladder dysfunction

**3. Non-classic form or Atypical form** – Rare

- ✓ Seizures
- ✓ Slowly progressive course
- ✓ Autonomic dysfunction
- ✓ Oculogyric crisis

- ✓ Stage - 4 (**Coma**) – Usually begins within 10 days of stage - 3
- ✓ Stage – 5 – **Death**
- ✓ Following the onset of stage 4, without supportive care, **most patients die** within two to three days
- ✓ **Even with supportive therapy, virtually zero patients survive rabies**

[Am J Trop Med Hyg.](#) 2019 Jan; 100(1): 165–169.

Published online 2018 Nov 5. doi: [10.4269/ajtmh.18-0711](https://doi.org/10.4269/ajtmh.18-0711)

PMCID: [PMC6335910](https://pubmed.ncbi.nlm.nih.gov/PMC6335910/)

PMID: [30398147](https://pubmed.ncbi.nlm.nih.gov/30398147/)

## Case Reports: Survival from Rabies: Case Series from India

[Reeta S. Mani](#),<sup>1,\*</sup> [Tina Damodar](#),<sup>1</sup> [Divyashree S.](#),<sup>1,2</sup> [Srikanth Domala](#),<sup>3</sup> [Birendra Gurung](#),<sup>4</sup> [Vilas Jadhav](#),<sup>5</sup>  
[Ramesh Konanki](#),<sup>3</sup> [Lokesh Lingappa](#),<sup>3</sup> [Sathish Kumar Loganathan](#),<sup>6</sup> [Rajendra Salagare](#),<sup>7</sup> and [Priyash Tambi](#)<sup>8</sup>




- ✓ This is a case series from India describing the clinical and radiological findings of eight patients with laboratory confirmed rabies who survived the illness (ranging from up to 5 months to > 1 year post onset of symptoms)
- ✓ All of them had World Health Organization (WHO) category III rabies virus exposures through dog bites
- ✓ Wound management and anti-rabies vaccination (ARV) were initiated on the day of exposure in all patients, except in one case where ARV was initiated 12 days after the dog bite
- ✓ Only 3/8 (37.5%) received rabies immunoglobulin (RIG)

Details of patients with laboratory-confirmed rabies (n = 8)

| Case no. | Age/gender; state; month and year of disease onset | Mode and site of exposure; World Health Organization category of exposure | Vaccine type, dose, and site                                      | Type of rabies immunoglobulin; site (local and systemic) | Incubation period (days) | Presenting clinical features  | Magnetic resonance imaging findings (day post onset of symptoms)  | Neurological sequelae | Outcome/duration of survival (as of June 30, 2018) |
|----------|--|---|---|--|--------------------------|---|---|-----------------------|--|
| 1        | 13 years/M; Sikkim; June 2016                      | Dog bite; right leg; category III   | PCEC; five doses; IM; site unknown (initiated 12 days after bite) | None   | 90                       | Fever of 2 weeks duration, breathlessness, paralysis, and aerophobia  | Not carried out   | Severe                | Died after 5 months of survival                    |
| 2        | 10 years/M; Andhra Pradesh; January 2015           | Dog bite; right thigh and right loin; category III                        | PCEC; three doses; IM (site unknown)                              | None   | 17                       | Fever of 7 days duration, lethargy, and altered sensorium since 2 days  | Bilateral bulky and long basal ganglia (right > left). Gyral swelling in the right posterior parietal cortex, showing mild diffusion restriction (day 8)  | Severe                | Died after 6 months of survival                    |
| 3        | 5 years/F; Karnataka; December 2016                | Dog bite; right leg; category III   | PCEC; three doses; IM (site unknown)                              | None   | 20                       | Fever of 10 days duration, followed by vomiting and drowsiness, and altered sensorium of 1 week duration                          | Not carried out   | Severe                | Died after 8 months of survival                    |
| 4        | 3 years/F; Maharashtra; October 2017               | Dog bite; left hand (ring finger); category III                           | PCEC; five doses; IM (deltoid and gluteal regions)                | None   | 25                       | Excessive sleep, lethargy, drowsiness, inability to walk, no spontaneous eye movement, no response to verbal commands             | Lesions in the dorsal brainstem; thalamus and basal ganglia also involved (day 7)   | Moderate              | 6 months (still surviving)                         |
| 5        | 5 years/F; Maharashtra; November 2017              | Dog bite; right side of shoulder, chest, and hip; category III            | PCEC; four doses; IM (deltoid)                                    | Human rabies immunoglobulin (local and IM)               | 19                       | Fever with chills of 6 days duration, drowsiness, and projectile vomiting of 2 days duration                                      | T2/FLAIR hyperintensities seen in the bilateral parieto-occipital region (cortical), bilateral thalami, right putamen, and right insular cortex without any abnormal susceptibility on SWI or restriction on DWI (day 10) | Severe                | 7.5 months (still surviving)                       |
| 6        | 4 years/M; Maharashtra; August 2017                | Dog bite; right eyebrow; category III                                     | PCEC; three doses; IM (triceps)                                   | ERIG (local and IM)                                      | 20                       | Fever, altered sensorium, oculogyric crisis of 1-week duration  | Midbrain and cervicomedullary T2 hyperintensities (day 4)   | Severe                | 10 months (still surviving)                        |
| 7        | 26 years/M; Maharashtra; April 2017                | Dog bite; face; category III  | PCEC; four doses; IM (deltoid)                                    | None   | 16                       | Fever, body ache, ear discomfort, diplopia, difficulty walking, behavioral changes—restlessness, excessive and irrelevant talking | Abnormal T2 and flair hyperintensities over bilateral basal ganglia. Abnormal T2 hyperintensities involving pons and medulla (day 1)  | Moderate              | 13 months (still surviving)                        |
| 8        | 9 years/M; Telangana; April 2017                   | Dog bite; dorsal aspect of left mid-forearm; category III                 | PCEC; four doses; IM (site unknown)                               | ERIG—local (20 days after bite)                          | 15                       | Fever, pain in the left upper limb, neck pain for 8 days, agitation and somnolence since 3 days                                   | T2W and FLAIR hyperintensities in dorsal midbrain, dorsal pons, and cervical spinal cord upto C7 level suggestive of rhombencephalitis and myelitis (day 7) (Figure 1)  | Mild                  | 13 months (still surviving)                        |

Details of patients with laboratory-confirmed rabies ( $n = 8$ )

| Case no. | Age/gender; state; month and year of disease onset | Mode and site of exposure; World Health Organization category of exposure | Vaccine type, dose, and site                                      | Type of rabies immunoglobulin; site (local and systemic) | Incubation period (days) | Presenting clinical features  | Magnetic resonance imaging findings (day post onset of symptoms)  | Neurological sequelae | Outcome/duration of survival (as of June 30, 2018) |
|----------|--|---|---|--|--------------------------|---|---|-----------------------|--|
| 1        | 13 years/M; Sikkim; June 2016                      | Dog bite; right leg; category III   | PCEC; five doses; IM; site unknown (initiated 12 days after bite) | None   | 90                       | Fever of 2 weeks duration, breathlessness, paralysis, and aerophobia  | Not carried out   | Severe                | Died after 5 months of survival                    |
| 2        | 10 years/M; Andhra Pradesh; January 2015           | Dog bite; right thigh and right loin; category III                        | PCEC; three doses; IM (site unknown)                              | None   | 17                       | Fever of 7 days duration, lethargy, and altered sensorium since 2 days  | Bilateral bulky and long basal ganglia (right > left). Gyral swelling in the right posterior parietal cortex, showing mild diffusion restriction (day 8)  | Severe                | Died after 6 months of survival                    |
| 3        | 5 years/F; Karnataka; December 2016                | Dog bite; right leg; category III   | PCEC; three doses; IM (site unknown)                              | None   | 20                       | Fever of 10 days duration, followed by vomiting and drowsiness, and altered sensorium of 1 week duration                          | Not carried out   | Severe                | Died after 8 months of survival                    |
| 4        | 3 years/F; Maharashtra; October 2017               | Dog bite; left hand (ring finger); category III                           | PCEC; five doses; IM (deltoid and gluteal regions)                | None   | 25                       | Excessive sleep, lethargy, drowsiness, inability to walk, no spontaneous eye movement, no response to verbal commands             | Lesions in the dorsal brainstem; thalamus and basal ganglia also involved (day 7)   | Moderate              | 6 months (still surviving)                         |
| 5        | 5 years/F; Maharashtra; November 2017              | Dog bite; right side of shoulder, chest, and hip; category III            | PCEC; four doses; IM (deltoid)                                    | Human rabies immunoglobulin (local and IM)               | 19                       | Fever with chills of 6 days duration, drowsiness, and projectile vomiting of 2 days duration                                      | T2/FLAIR hyperintensities seen in the bilateral parieto-occipital region (cortical), bilateral thalami, right putamen, and right insular cortex without any abnormal susceptibility on SWI or restriction on DWI (day 10) | Severe                | 7.5 months (still surviving)                       |
| 6        | 4 years/M; Maharashtra; August 2017                | Dog bite; right eyebrow; category III                                     | PCEC; three doses; IM (triceps)                                   | ERIG (local and IM)                                      | 20                       | Fever, altered sensorium, oculogyric crisis of 1-week duration  | Midbrain and cervicomedullary T2 hyperintensities (day 4)   | Severe                | 10 months (still surviving)                        |
| 7        | 26 years/M; Maharashtra; April 2017                | Dog bite; face; category III  | PCEC; four doses; IM (deltoid)                                    | None   | 16                       | Fever, body ache, ear discomfort, diplopia, difficulty walking, behavioral changes—restlessness, excessive and irrelevant talking | Abnormal T2 and flair hyperintensities over bilateral basal ganglia. Abnormal T2 hyperintensities involving pons and medulla (day 1)  | Moderate              | 13 months (still surviving)                        |
| 8        | 9 years/M; Telangana; April 2017                   | Dog bite; dorsal aspect of left mid-forearm; category III                 | PCEC; four doses; IM (site unknown)                               | ERIG—local (20 days after bite)                          | 15                       | Fever, pain in the left upper limb, neck pain for 8 days, agitation and somnolence since 3 days                                   | T2W and FLAIR hyperintensities in dorsal midbrain, dorsal pons, and cervical spinal cord upto C7 level suggestive of rhombencephalitis and myelitis (day 7) (Figure 1)  | Mild                  | 13 months (still surviving)                        |



✓ Patients who have received **prior vaccination** but develop rabies



✓ Rapidly **develop high concentrations of serum and CSF-neutralizing antibodies**



✓ **Possibly leading to viral clearance**



✓ Explains the **low sensitivity of PCR** which was seen in our case



✓ Administration of vaccine and RIG



✓ Alters the pathogenicity and natural progression of rabies virus infection



**✓ Leading to atypical presentation of rabies encephalitis and survival**

- ✓ Currently, there is no antiviral of proven efficacy in human rabies
- ✓ A unique treatment, the “**Milwaukee Protocol**” which included **induced coma** and **anti-excitotoxic therapy** was credited with the survival of an unvaccinated teenager with **bat rabies encephalitis** in 2005
- ✓ However, multiple efforts to **replicate this protocol have not been largely successful**
- ✓ The Milwaukee Protocol, in its current version, is a supportive critical care

# Conclusion

- ✓ This is the 5<sup>th</sup> documented case from Maharashtra and 9<sup>th</sup> case from India who has survived rabies
- ✓ It highlights the **tragic occurrence of the disease despite vaccination and IG administration**
- ✓ It also emphasizes the **importance of post exposure prophylaxis and post exposure prophylaxis protocols** which should be strictly followed during administration of the vaccine and Immunoglobulin
- ✓ The primary focus, therefore, should be on the “**prevention**” of rabies by preventing animal bite
- ✓ Increasing awareness about the disease and PEP protocols among the public and health-care professionals in rabies endemic countries
- ✓ Providing pre exposure prophylaxis in high risk individuals

# Acknowledgement

I would like to thank –

- ✓ Department of Radiodiagnosis
- ✓ Department of Microbiology
- ✓ National Institute of Virology, Pune

Thank you!